source
- AdvanCell secures $315M Series D to advance lead-based prostate cancer therapyAdvanCell announced a $315 million Series D financing round aimed at supporting development of its lead-based prostate cancer agent and expanding U.S. manufacturing capacity for the radioactive tre…
- J&J reports 18,000 new prescriptions for Icotyde in first full quarterJohnson & Johnson gave an update on the launch of its plaque-psoriasis drug Icotyde. The company said that in its first full quarter on the market, Icotyde generated about 18,000 new prescriptions…